Testosterone Treatment Lawsuits Move Forward With Scheduling of First Status Conference in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) June 22, 2014 -- The federal multidistrict litigation established in the U.S. District Court, Northern District of Illinois, for federally-filed testosterone treatment lawsuits (http://www.testosteronelawsuitclaims.com/) is beginning to move forward, Bernstein Liebhard LLP reports. According to a Case Management Order dated June 6th, the Court will convene the litigation’s initial Status Conference on July 10, 2014. The Order also stays all discovery and motions pending the initial conference and further orders from the Court. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
“Our Firm is investigating a number of potential testosterone lawsuits on behalf of men who allegedly suffered heart attacks, strokes and other life threatening heart events due to their use of low testosterone therapies. We are pleased to see that this proceeding is getting underway,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm offers free testosterone treatment lawsuit reviews to men who were allegedly harmed by medications included in this class.
Testosterone Lawsuits
According to court documents, at least 98 testosterone treatment lawsuits have been filed in the Northern District of Illinois on behalf of men who allegedly suffered heart attacks, strokes, heart failure, deep vein thrombosis, pulmonary embolism, and other cardiac problems due to their use of prescription low testosterone therapies. The litigation involving these medications began to grow in the wake of a January 2014 announcement by the U .S. Food & Drug Administration (FDA) that it was investigating cardiovascular risks potentially associated with the drugs. The FDA’s review was prompted by the publication of studies that indicated the use of testosterone replacement therapies may increase the risk that some men will suffer heart attacks, stroke, or cardiovascular death.
Though the majority of claims filed thus far in the federal proceeding involve AndroGel, court records indicate that the litigation was established to coordinate product liability lawsuits involving any drug in this class. Among other things, plaintiffs in these lawsuits allege that many men undergoing testosterone replacement had no medical reason to do so but were induced to seek treatment by marketing claims that characterized low testosterone therapy as a remedy for weight gain, low libido, fatigue and other symptoms associated with the aging process.
Men who used low testosterone therapy may be entitled to file a testosterone lawsuit if they suffered a heart attack, stroke or other heart problem allegedly associated with this class of medications. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.testosteronelawsuitclaims.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Testosterone Lawsuit Claims Center, http://www.testosteronelawsuitclaims.com/, +1 800-511-5092, [email protected]
Share this article